333: An H5N1 bird flu update and talent scarcity in the radiopharma field
You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and...
5 Joulu 202427min
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allis...
21 Marras 202435min
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard? We talk about all that and m...
14 Marras 202430min
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA reporter, Baird analyst Brian Skorney, and longtime biot...
7 Marras 202439min
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly and Pfizer's surprise earnings reports. Then, they discuss what a Trump or Harris p...
31 Loka 202428min
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duche...
24 Loka 202433min
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Elaine, Allison, and Adam chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the inv...
17 Loka 202434min
326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
First, biotech veteran John Maraganore calls in to discuss his new startup, City Therapeutics, this week's Nobel Prize awards, and the nerdy accolade he just received. Then STAT's Megan Molteni tells ...
10 Loka 202440min
